Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - Cardiff Oncology, Inc. | d584926ds1a.htm |
| EX-4.9 - EX-4.9 - Cardiff Oncology, Inc. | d584926dex49.htm |
| EX-3.5 - EX-3.5 - Cardiff Oncology, Inc. | d584926dex35.htm |
| EX-3.6 - EX-3.6 - Cardiff Oncology, Inc. | d584926dex36.htm |
| EX-5.1 - EX-5.1 - Cardiff Oncology, Inc. | d584926dex51.htm |
| EX-1.1 - EX-1.1 - Cardiff Oncology, Inc. | d584926dex11.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Trovagene, Inc.
San Diego, California
We hereby consent to the use in this Prospectus of this Amendment No. 1 to the Registration Statement on Form S-1 of our report dated February 26, 2018, except for the effects of the reverse stock split described in Note 15, as to which the date is June 4, 2018, relating to the consolidated financial statements of Trovagene, Inc. (the “Company”), which appears in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
San Diego, California
June 4, 2018